Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Abbott Laboratories : Secures FDA Approval for MRI-Compatibility for the Company's Ellipse™ ICD

share with twitter share with LinkedIn share with facebook
share via e-mail
09/22/2017 | 02:10pm CEST

Abbott Secures FDA Approval for MRI-Compatibility for the Company's Ellipse™ ICD


ABBOTT PARK, Ill., Sept. 22, 2017/PRNewswire / -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for one of Abbott's most widely-used implantable cardioverter defibrillators (ICD) and associated high voltage leads. The approval of MR-conditional labeling for the Ellipse™ ICD with the Tendril MRI pacing lead and Durata and Optisure high voltage leads adds another patient-centric benefit to the device and will help further improve access for patients suffering from abnormally fast heart rhythms who need an ICD and who may need an MRI scan in the future.

When electrical signals in the lower chamber of the heart fire erratically, the heart can beat abnormally fast - a condition known as ventricular tachycardia or tachyarrhythmia - which in turn leaves the heart unable to pump blood effectively. In addition to symptoms such as light-headedness, chest pains and shortness of breath, over time the condition can lead to a potentially life-threatening arrhythmia, heart failure, stroke or cardiac arrest. Abbott's ICD devices can monitor for and detect abnormally fast heart rhythms and deliver electricity to the heart to restore the heart's natural rhythm.

The new MR-conditional labeling for the Ellipse ICD allows patients to undergo an MRI scan if needed. In addition, patients previously implanted with an Ellipse device and Durata or Optisure leads can now undergo MRI scans.

'When you consider the number of patients each year who rely on the lifesaving treatment delivered by an ICD device, it is critical to continually innovate to provide new benefits to people battling complex arrhythmias and other cardiac conditions,' said Mark Carlson, M.D., chief medical officer for Abbott's Cardiac Arrhythmias and Heart Failure division. 'By expanding our portfolio of MRI compatible devices, we're adding another benefit onto an ICD device that was designed hand-in-hand with physicians to optimize therapy for patients.'

The smaller shape and size of Ellipse ICD helps improve patient comfort once implanted and Abbott engineered the device with features designed to optimize ICD therapy and improve patient safety. The features, known as Abbott's TailoredTherapy™ approach, include:

  • DeFT Response™ Technology: Allows physicians to adapt how therapy is delivered by the Ellipse ICD to ensure each patient receives therapy based on their unique need. The feature also helps ensure successful therapy delivery without the need to deliver an initial shock at the time of implant.
  • SecureSense™: Abbott's SecureSense algorithm offers an additional level of protection for patients by providing proper sensing within the heart even in the presence of external interference (known as 'lead noise') to safeguard against unnecessary therapy being delivered to the patient.
  • DynamicTx™: With Abbott's DynamicTx algorithm, physicians can be confident that their patient's devices are consistently evaluating the condition of the lead and adapting the path of the electrical impulse to deliver appropriate therapy.

As a further benefit, all therapy and other data captured by the Ellipse ICD can be directly, securely and wirelessly sent to a patient's physician through the Merlin.net™ Patient Care Network. This communication allows physicians to remotely monitor their patient's therapy and assess any need for intervention.

The latest labeling ensuring Abbott's Ellipse ICD is MRI ready follows approval earlier this year of Abbott's Assurity MRI pacemaker and prior MR-conditional labeling approvals in Europe, allowing Abbott to further build its portfolio of MRI ready products. The company continues to work with regulatory agencies around the world to secure approval for MR-conditional labeling for additional commonly-implanted pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices.

An ICD is an advanced high voltage implantable device that treats potentially lethal, abnormally fast heart rhythms, which often lead to sudden cardiac death. Each year, more 300,000 ICDs are implanted worldwide.

A lead is a thin insulated wire that is placed through the vein as part of a pacemaker or ICD implantation procedure. The tip of the lead is attached to the heart tissue, and the other end connects to the ICD. A lead carries electrical impulses from the ICD to the heart and transmits information from the heart back to the implanted device.

Some ICDs are referred to as 'MR-conditional' or 'MRI ready.' This means that they are designed to allow patients to safely undergo an MRI scan under certain conditions. By having an ICD implanted that allows MRI scans, patients have access to an imaging modality that offers important information and highly detailed images to medical professionals when making a patient diagnosis.

For more information about Abbott's focus on cardiac rhythm management, visit www.sjm.com/en/patients/arrhythmias.

About Abbott:
At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.


For further information: Abbott Media, Justin Paquette, 651-756-6293; Abbott Financial, Mike Comilla, 224-668-1872

Abbott Laboratories published this content on 22 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 September 2017 12:09:03 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
02:10p ABBOTT LABORATORIES : Secures FDA Approval for MRI-Compatibility for the Company..
02:01p ABBOTT : Secures FDA Approval for MRI-Compatibility for the Company's Ellipse(TM..
09/21 ABBOTT LABORATORIES : Patent Issued for Nutritional Compositions Including Calci..
09/20 ABBOTT : Hosts Conference Call for Third-Quarter Earnings
09/20 ABBOTT LABORATORIES : Lawsuit seeks damages for faulty batteries in St. Jude def..
09/18 ABBOTT LABORATORIES : and the Fund Expand Support for Hurricane Relief with $1 M..
09/15 ABBOTT LABORATORIES : FreeStyle Libre Flash Glucose Monitoring Technology Gains ..
09/14 ABBOTT LABORATORIES : Landmark Study Published in the New England Journal of Med..
09/14 ABBOTT LABORATORIES : Trademark Application for "INSULINX" Filed by Abbott Labor..
09/14 ABBOTT LABORATORIES : An Application for the Trademark "FREESTYLE INSULINX" Has ..
More news
News from SeekingAlpha
08:17a FDA OKs MR labeling for Abbott's Ellipse ICD
09/21 Medical Devices Are The Quiet Growth Sector
09/19 MYLAN : Time To Sell?
09/19 I Was Right, There Was An Alpha Opportunity With My 15 Dividend Achievers
09/18 Buy Abbott Laboratories - Cramer's Lightning Round (9/15/17)
Financials ($)
Sales 2017 26 470 M
EBIT 2017 5 762 M
Net income 2017 2 348 M
Debt 2017 14 989 M
Yield 2017 2,08%
P/E ratio 2017 47,26
P/E ratio 2018 26,57
EV / Sales 2017 3,94x
EV / Sales 2018 3,66x
Capitalization 89 357 M
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 54,9 $
Spread / Average Target 6,8%
EPS Revisions
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.63%353 617
NOVARTIS11.88%223 850
ROCHE HOLDING LTD.6.19%221 926
PFIZER10.81%214 206
MERCK AND COMPANY11.75%178 914